{"organizations": ["Wave Life Sciences", "Life Sciences"], "uuid": "055790740613a0be5f236ed0d4ed22105ef3cbd0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530638?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Wave Life Sciences raises $66mm in Series B offering", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Wave Life Sciences raises $66mm in Series B offering", "spam_score": 0.0, "site_type": "news", "published": "2015-08-20T02:40:00.000+03:00", "replies_count": 0, "uuid": "055790740613a0be5f236ed0d4ed22105ef3cbd0"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530638?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Wave Life Sciences raises $66mm in Series B offering", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Wave Life Sciences raises $66mm in Series B offering Deal Date: Aug-01-2015 / Deal # 201530638 Executive Summary \nGenetic medicine company Wave Life Sciences raised $66mm in an oversubscribed Series B preferred stock financing. The funding was led by Foresite Capital with participation from Fidelity Management, New Leaf Venture Partners, Redmile Group, Jennison Associates, Comorant Asset Management, RA Capital Management, Kagoshima Shinsangyo Sosei Investment, and private investment funds advised by Clough Capital Partners LP. Leerink Partners was the placement agent. Wave will use the proceeds for its chemistry platform and to further develop its pipeline of stereopure nucleic acid therapeutics for Huntington's disease and Duchenne muscular dystrophy.", "external_links": [], "published": "2015-08-20T02:40:00.000+03:00", "crawled": "2015-08-21T18:04:54.608+03:00", "highlightTitle": ""}